Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 11, 2023

Safety and Efficacy of Oral VV116 vs Placebo in Patients With Mild to Moderate COVID-19 in China

The Lancet Infectious Diseases

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Infectious Diseases
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Lancet Infect Dis 2023 Nov 22;[EPub Ahead of Print], X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng, C Huang, H Liu, H Lu, X Shen, W Zhang, F Wang, G Li, M Li, Y Huang, H Zhang, M Li, F Ren, Y Li, C Liu, Z Zhou, W Sun, Y Yi, D Zhou, H Gao, Q Pan, H Liu, J Zhao, Z Ding, Y Ma, W Li, Q Wang, X Wang, Y Bai, X Jiang, J Ma, B Xie, K Zhang, L Li

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading